Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679095 | 0.95 | ALDH1A1 (0.50) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL16193422 | 0.87 | ALDH1A1 (0.44) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL12255396 | 0.86 | RXRA (0.43) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL257565 | 0.86 | RXRA (0.43) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL2522090 | 0.86 | RXRA (0.43) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL30181252 | 0.86 | RXRA (0.43) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL4804364 | 0.84 | RXRA (0.42) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL1344359 | 0.84 | RXRA (0.42) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL17922590 | 0.84 | RXRA (0.42) | ALDH1A1PTGS1RXRARXRBRXRG | |
| SCHEMBL5783571 | 0.84 | NOTUM (0.51) | ALDH1A1PTGS1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683918-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024193541-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-09-26 | — | — | WO | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| US-5731340-A | DIETETICS; ANTIDIABETIC AGENTS | SANOFI (FR) | 1998-03-24 | — | — | US | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| CN-1131144-A | Glycinamide derivatives, processes for their preparation and medicines containing them | SANOFI SA (FR) | 1996-09-18 | — | — | CN | disclosed |
| EP-0697403-A1 | Derivatives of glycinamides as cholecystokinin receptor agonists | SANOFI (FR) | 1996-02-21 | — | — | EP | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | ALDH1A1 415/4885PTGS1 1766/4885RXRA 30/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | ALDH1A1 415/4885PTGS1 1766/4885RXRA 30/4885 |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ALDH1A1 312/4885PTGS1 778/4885RXRA 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.